<DOC>
	<DOCNO>NCT00727103</DOCNO>
	<brief_summary>The aim propose pilot study find whether varenicline ( ChantixTM ) treatment decrease alcohol use smoking patient schizophrenia schizoaffective disorder . Varenicline may also improve cognition ( memory concentration ) negative symptom ( e.g . poor attention , poverty speech , apathy , affective flattening , anhedonia ) patient schizophrenia comorbid nicotine alcohol dependence .</brief_summary>
	<brief_title>Varenicline Treatment Alcohol Nicotine Dependent Patients With Schizophrenia</brief_title>
	<detailed_description>Alcohol use ( 33 % ) smoking ( 80-90 % ) commonly occur together patient schizophrenia . Varenicline ( ChantixTM ) approve FDA medication smoke cessation . Recent animal study show chronic varenicline administration decrease alcohol consumption . There human data available effectiveness varenicline alcohol-use disorder . The aim propose pilot study find whether varenicline treatment decrease alcohol use smoking patient schizophrenia schizoaffective disorder . Varenicline may also improve cognition ( memory concentration ) negative symptom ( e.g . poor attention , poverty speech , apathy , affective flattening , anhedonia ) patient schizophrenia comorbid nicotine alcohol dependence . The propose pilot study enroll cohort 30 subject schizophrenia schizoaffective disorder nicotine alcohol dependence , receive ongoing outpatient mental health treatment community provider . Subjects randomly assign one two treatment group ( varenicline vs. placebo ) . Following one week screen phase , participant see day 4 , day 8 , weekly 8-week treatment period . One week supply medication dispense study visit , exception first week , 4 day supply give 2 day ( visit 1 2 ) . One month discontinuation medication , follow-up interview conduct . Varenicline placebo dispense 0.5 mg 1 mg color cod capsule . During first 3 day treatment , participant take one 0.5 mg tablet varenicline ( placebo ) mouth daily . If medication well-tolerated , dose increase 0.5 mg mouth twice daily 4 day . From day 8 , dose increase standard dosing schedule 1 mg ( 1 tablet ) mouth twice daily . At end 8th week , varenicline discontinue . A structured clinical psychiatric interview physical exam perform baseline , along urine drug screen , repeat week 8 , 1 month follow-up . Blood test ( complete blood count , basic metabolic panel , liver function test ) perform baseline , monthly . During weekly study visit patient undergo breath carbon-monoxide breath alcohol testing , answer question depression , smoke alcohol use . Detailed assessment psychiatric symptom severity ( include neuropsychological testing ) perform baseline , end treatment phase ( week 8 ) . A functional MRI study perform baseline end study assess change blood flow , emotional processing work memory related varenicline treatment . In addition , genetic polymorphism α4β2 nicotinic acetylcholine receptor gene expression change relate drinking/smoking/psychosis varenicline treatment also assess . The primary objective propose study two fold : first determine feasibility conduct similar study large scale , second establish pilot data determine effect size hypothesize treatment effect alcohol nicotine use base objective test self report . These estimate help inform minimum sample size need large future trial .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Males female , age 18 69 , DSMIV diagnosis Schizophrenia Schizoaffective Disorder , receive outpatient psychiatric treatment Currently take antipsychotic medication least 4 week ( medication prescribe , compliance assess base selfreport collateral information ) Current DSMIV diagnosis Nicotine Dependence Current DSMIV diagnosis Alcohol Dependence Subject express desire cut quit smoke drinking ( base assessment contemplation ladder ) An average least one pack cigarettes per day ( &gt; =20 cigarettes/day ) 7 day prior intake An average least 7 drink 7 day prior intake Inability give adequate inform consent Currently take sustained release bupropion ( Zyban ) receive form bupropion , Wellbutrin Wellbutrin SR ; receive another form pharmacological smoking cessation treatment ( e.g. , nicotine gum patch ) ; participate another structure , formal smoking cessation program . Currently take naltrexone ( ReVia ) , Campral Antabuse Participation clinical trial le 3 month prior intake History suicide attempt past year History hospitalization due suicidal ideation past year Suicidal ideation baseline Known allergic reaction varenicline Female patient childbearing potential sexually active , sterile , deny use form birth control . Female patient pregnant nursing . Significant unstable medical problem ( e.g . impaired renal function ) . Significant unstable psychiatric disorder . Subjects attend require screening appointment . Subjects pending legal proceeding whose outcome may lead incarceration within 3 month intake . Positive urine drug screen cocaine , opioids amphetamine baseline Current DSMIV diagnosis Cocaine , Opioid Cannabis Dependence ( 1 month prior enrollment ) Metal implant device ( e.g . aneurysm clip , cochlear implant , neural stimulators , cardiac pacemaker ) Weight 250 lb Claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Varenicline</keyword>
	<keyword>Smoking cessation</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective disorder</keyword>
	<keyword>Alcohol dependence</keyword>
	<keyword>Nicotine dependence</keyword>
</DOC>